Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Toll-Like Receptor 9
A pattern recognition receptor that binds unmethylated CPG CLUSTERS. It mediates cellular responses to bacterial pathogens by distinguishing between self and bacterial DNA.
Year introduced: 2006(2001)
CPG 10101 [Supplementary Concept]
a potent and selective unmethylated cytidine-phosphate-guanosine (CpG)-containing oligodeoxynucleotide agonist of Toll-like receptor 9 (TLR9) for the treatment of chronic infections such as HCV
Date introduced: October 17, 2007
HYB-2055 [Supplementary Concept]
immunomodulatory oligonucleotide, an agonist of toll-like receptor 9, for the potential treatment of cancer; in phase II clinical trials (8/2005)
Date introduced: December 28, 2005
TLR9 protein, human [Supplementary Concept]
RefSeq NM_017442
Date introduced: July 29, 2005
Tlr9 protein, mouse [Supplementary Concept]
RefSeq NM_031178
Tlr9 protein, rat [Supplementary Concept]
RefSeq NM_198131
Date introduced: September 10, 2004
cobitolimod [Supplementary Concept]
DNA based oligonucleotide that activates toll-like receptor 9
Date introduced: December 15, 2020
iCpG-ODN [Supplementary Concept]
toll-like receptor 9 (TLR9) antagonist; has anti-inflammatory activity in response to cerebral ischemia or reperfusion injury in mice
Date introduced: May 4, 2018
6-N-methylnaltrexamine [Supplementary Concept]
a toll-like receptor 9 antagonist; structure in first source
Date introduced: May 21, 2017
ODN2006 [Supplementary Concept]
a toll-like receptor 9 (TLR9) agonist
Date introduced: March 14, 2017